Key statistics
On Friday, CERo Therapeutics Holdings Inc (CERO:NMQ) closed at 0.2181, 242.92% above the 52 week low of 0.0636 set on Nov 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.2323 |
---|---|
High | 0.2465 |
Low | 0.2067 |
Bid | 0.2104 |
Offer | 0.2178 |
Previous close | 0.2479 |
Average volume | 393.97m |
---|---|
Shares outstanding | 147.54m |
Free float | 61.18m |
P/E (TTM) | -- |
Market cap | 36.58m USD |
EPS (TTM) | -0.3796 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
- CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
- CERo Therapeutics, Inc. Provides Corporate Update
- CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
- CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236
- CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024
- CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
- CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
- CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
More ▼